Signal2026-07-01
ClinicalTrials.gov

[PHASE2] Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

Part of

Dynamic Medicine And Treatment Timing

Open primary sourceSee the whole picture